#United States #Pittsburgh #quarterly dividend #Viatris Inc. #NASDAQ VTRS

Viatris Declares Quarterly Dividend

On November 3, 2025, Viatris Inc. (Nasdaq: VTRS) revealed that its Board of Directors approved a quarterly dividend of $0.12 for each common share that is issued and outstanding. This move is part of the company’s ongoing commitment to providing value to its shareholders.

The declared dividend is set to be paid on December 15, 2025, to all shareholders who are on record by the close of business on November 24, 2025. This initiative highlights Viatris's dedication to ensuring consistent returns to its shareholders, even amidst the evolving dynamics of the global healthcare landscape.

About Viatris Inc.

Viatris is a prominent global healthcare entity, uniquely positioned to combine the advantages of generic pharmaceuticals with established brand names. The company's mission is focused on empowering individuals worldwide to lead healthier lives at various life stages. To achieve this, Viatris provides access to a broad range of high-quality medications, currently serving around 1 billion patients annually across the globe.

With a remarkable portfolio addressing everything from acute ailments to chronic conditions, Viatris strives to meet healthcare needs comprehensively. Headquartered in the U.S., the company has crucial operations in Pittsburgh, Shanghai, and Hyderabad, India. Its extensive global supply chain is designed to reach populations in need, emphasizing accessibility to healthcare solutions.

This recent dividend declaration reflects Viatris’s robust financial performance and commitment to shareholder value. The Board's decision is particularly significant amidst an ongoing focus on enhancing company operations and product development to meet escalating global health demands.

Forward-Looking Statements

It is important to address that this announcement includes forward-looking statements regarding Viatris's financial outlook and market conditions. Given the inherent uncertainties in the healthcare sector, factors such as regulatory changes and market dynamics could have a significant impact on the company's performance.

Viatris emphasizes its proactive approach to risk management and its commitment to transparent communication with investors regarding financial developments and potential challenges.

In summary, the approval of the dividend is not just a financial strategy but a reflection of Viatris's confidence in its business model and growth plans. Shareholders can look forward to receiving their dividends on the specified date, which reinforces the company’s ongoing efforts to foster shareholder trust.

For more detailed information about Viatris Inc., shareholders and interested investors can visit their official website at viatris.com and follow the company's updates on various social media platforms, including LinkedIn, Instagram, YouTube, and X.

This latest financial move is just one of many anticipated announcements as Viatris continues to operate at the intersection of generic and branded pharmaceuticals, ultimately focusing on enhancing patient care and affordability around the globe.